RxDoctor Payments Data

Martin Degraw, MD

Family Medicine · New Bern, NCNPI 1851345920

Payments from drug & device makers

$6,869in general payments, 2019–2025

Across 326 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$1K
  • Johnson & Johnson$749
  • GSK$470
  • Abbott$342
  • Eisai Inc.$284
  • plus $3K from 43 others

What the payments were for

  • Speaking & faculty fees$1001%
  • Food & beverage$6,76498%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,869 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$27,510
Medicare patients
137
Services billed
605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methenamine Hippurate20$724
Atorvastatin Calcium74$598
Indapamide23$491
Mirtazapine18$446
Trazodone Hcl26$373
Ondansetron OdtOndansetron15$368
Metoprolol Succinate33$345
Bupropion Hcl SrBupropion Hcl14$332
Memantine Hcl17$290
Hydroxyzine Hcl11$264
Pantoprazole Sodium17$254
Famotidine13$242
Amlodipine Besylate45$236
Bupropion XlBupropion Hcl15$233
Levothyroxine Sodium31$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAMorphine Sulfate$87$20813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →